Connect your AI

Candel Therapeutics, Inc. CADL Current Debt

Current Debt at other companies

Bristol-Myers SquibbBMY

$2.31B-35.1%

AmgenAMGN

$5.44B+61.4%

Gilead SciencesGILD

$1.31B-53.2%

Replimune GroupREPL

$2.86M+3.0%

ImmunityBio, Inc.IBRX

——

Other financials

Income statement

Revenue$31.0K0.0%

Operating income-$16.3M-100%

Net income-$8.9M-220%

EPS (diluted)-$0.14-208%

Balance sheet

Cash & equivalents$194.8M+111%

Total debt$2.8M-73.9%

Total equity$138.0M+84.8%

Total assets$201.9M+111%

Cash flow

Operating cash flow-$18.0M-109%

CapEx$675.0K+22,400%

Free cash flow-$18.7M-117%

Valuation

Market cap$693.87M+192%

Enterprise value$501.88M+220%

P/S5,595.7×-18,674×

Profitability

Operating margin-28,000.8%+15,050pp

Net margin-15,156.5%-5,064pp

FCF margin-26,383.9%+14,851pp

Returns & leverage

Return on equity-51.2%-16.6pp

Debt / equity0×-0.1×

Current ratio28×+23.4×

Where this comes from

Reported directly by Candel Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtCurrent.

The official record: Candel Therapeutics, Inc.’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Candel Therapeutics, Inc.'s current debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Candel Therapeutics, Inc.'s current debt?: Candel Therapeutics, Inc. (CADL) reported current debt of $0 in Q4 2025.
How has Candel Therapeutics, Inc.'s current debt changed year-over-year?: Candel Therapeutics, Inc.'s current debt decreased by 100.0% year-over-year, from $9.9M to $0.
What is the long-term trend for Candel Therapeutics, Inc.'s current debt?: Over 2 years (2023 to 2025), Candel Therapeutics, Inc.'s current debt has grown at a -100.0% compound annual growth rate (CAGR), from $8.89M to $0.
What does current debt mean?: The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.